Aizenscience-Incurix, Joint Research Agreement for Innovative Anticancer Drug Development Using Artificial Intelligence

Kang Jae-woo, CEO of Eisen Science (left), and Jung Kyung-chae, CEO of Incurex, are posing for a commemorative photo after signing the contract.

[Asia Economy Reporter Lee Gwan-joo] Aigen Science announced on the 21st that it has signed a joint research contract with new drug development company Incurex to develop innovative anticancer drugs based on artificial intelligence (AI).

This contract aims to jointly develop superior anticancer drugs by applying Aigen Science’s transcriptome data-based AI technology to the development of transcription factor inhibitors, which are recognized as important anticancer targets but are known to be difficult to develop.

Aigen Science will identify new substances that regulate transcription factors, which play a crucial role in cancer cell proliferation and survival, using its transcriptome-based AI drug development platform. Incurex will utilize and evaluate these substances through its proprietary transcription factor direct inhibitor drug development technology platform to discover new anticancer drug candidates, proceeding with joint development in this manner.

Aigen Science, an AI-based drug development company, possesses a drug development AI platform based on transcriptome profiles at the cellular level, differentiating itself from other AI drug developers that focus on protein structure. According to the contract, Aigen Science will use ‘AIGEN Discovery’ to initially screen about 10,000 compounds from a library of 3 billion compounds that show effects in regulating transcription factors at the cellular level. Subsequently, using the protein structure of the transcription factor, effective substances that bind with high affinity will be discovered, and lead compound discovery will be handled through optimization using ‘AIGEN Optimizer’.

Incurex will be responsible for validating the effective and lead compounds discovered by Aigen Science and for the subsequent development of candidate substances. Revenues secured through commercialization such as third-party technology transfers will be shared between the two companies at a certain ratio according to the development stage of the candidate substances at the time of revenue generation.

Kang Jae-woo, CEO of Aigen Science, said, “Through this joint development with Incurex, which specializes in developing anticancer drugs that directly inhibit transcription factors, we will successfully lead new drug development targeting transcription factors that have been difficult to approach with traditional drug development methods. Since Aigen Science’s AI platform is based on transcriptome data models, synergy is expected with Incurex, which has expertise in developing transcription factor inhibitors, and we have high expectations for the joint development going forward.”

Jung Kyung-chae, CEO of Incurex, said, “Through this joint development with Aigen Science, which has experience discovering candidate substances with a very high patentability rate compared to other AI companies, we will successfully proceed with ‘1st-in-Class’ new drug development targeting transcription factors.”

This content was produced with the assistance of AI translation services.